Catalyst Pharmaceuticals (CPRX) Share-based Compensation (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Share-based Compensation of $12.5 million for Q1 2026, up 172.07% on a QoQ basis from -$17.3 million in Q4 2025, and up 113.68% year-over-year from $5.8 million in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Share-based Compensation (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $12.5 million for Q1 2026.
- Quarterly Share-based Compensation rose 113.68% year-over-year to $12.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (up 822.54% YoY) and the FY2025 annual result came in at $39.1 million, down 6.24% from the prior year.
- Share-based Compensation was $12.5 million for Q1 2026 at Catalyst Pharmaceuticals, up from -$17.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $12.5 million in Q1 2026 and bottomed at -$17.3 million in Q4 2025.
- A 5-year average of $808117.6 and a median of $3.3 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation plunged 194.96% — and 2024, when it soared 1629.14%.
- Catalyst Pharmaceuticals' Share-based Compensation stood at -$5.8 million in 2022, then plunged by 56.81% to -$9.0 million in 2023, then sank by 81.99% to -$16.4 million in 2024, then declined by 5.68% to -$17.3 million in 2025, then soared by 172.07% to $12.5 million in 2026.
- Business Quant data shows CPRX's Share-based Compensation at $12.5 million in Q1 2026, -$17.3 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 12.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.50 Mn |
| Mar 31, 2026 | 12.50 Mn |
| Dec 31, 2025 | -17.34 Mn |
| Dec 31, 2025 | -17.34 Mn |
| Sep 30, 2025 | 5.67 Mn |
| Sep 30, 2025 | 5.67 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Mar 31, 2025 | 5.85 Mn |
| Mar 31, 2025 | 5.85 Mn |
| Dec 31, 2024 | -16.41 Mn |
| Dec 31, 2024 | -16.41 Mn |
| Sep 30, 2024 | 4.42 Mn |
| Sep 30, 2024 | 4.42 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Jun 30, 2024 | 4.41 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Dec 31, 2023 | -9.02 Mn |
| Dec 31, 2023 | -9.02 Mn |